Clinical Trial Update: Treatment of Recurrent GBM With APG-157 Via Expanded Access

View source ↗

Summary

Expanded-access trial of APG-157 for recurrent glioblastoma has been discontinued and is no longer available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Glioblastoma Multiforme

Drugs mentioned

• APG-157

Snippet

Sponsor: Aveta Biomics, Inc. | Conditions: Glioblastoma, Glioblastoma Multiforme | Status: NO_LONGER_AVAILABLE